Text Size

Pan-European Survey on the Under Treatment of Hypercholesterolemia (CEPHEUS)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00542867
First received: October 11, 2007
Last updated: November 19, 2007
Last verified: November 2007
History of Changes
  Purpose

The survey try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines, overall and by country.·


Condition
Hypercholesterolemia

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Pan-European Survey on the Under Treatment of Hypercholesterolemia

Resource links provided by NLM:

MedlinePlus related topics: Cholesterol
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The number and percentage of patients achieving the LDL-C goals, according to the Third Joint European Task Force guidelines, overall and by country.

Enrollment: 6500
Study Start Date: January 2006
Study Completion Date: November 2007
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients had to be on a lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00542867

Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: M. Hermans UCL
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00542867     History of Changes
Other Study ID Numbers: SRP-CB-CRE-2006/01
Study First Received: October 11, 2007
Last Updated: November 19, 2007
Health Authority: Belgium: Federal Agency for Medicinal Products and Health

Keywords provided by AstraZeneca:
Hypercholesterolemia
Third Joint European Task Force guidelines
Survey

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on October 17, 2012